Volgoat and wook have posted some nice history re use of Tarvacin a/k/a Bavituximab in treating various viral infections, particularly including Ebola, gathered from CJG and JBM in 2005-2008 time frame.
But the story does not end there...and it did end in 2011 as far as we know. It is detailed in the PPHM IBox maintained by CJG.
Some further thoughts:
Ebola: further odds and ends, including NIH vaccine activity, Tekmira, and an unidentified monoclonal, are discussed here in an article late Thursday:
Government funding seems to be headed to U.Texas at Galveston[how cooperative are UTSW and UTGalveston?]:
"The NIH recently gave Geisbert's lab a five-year, $26 million grant to research three of the most promising treatments for Ebola. These include a man-made antibody treatment[and what antibody might that be?]; a promising Canadian drug from Tekmira Pharmaceuticals shown to protect monkeys from Ebola; and a vaccine that can be used both to prevent infection and also treat it.
"One of our goals is to start combining these treatments, like we do with AIDS medications," Geisbert said.
He said there are a number of obstacles to bringing these drugs to the clinic.
"It's a very fast-moving disease, and you often don't have a lot of time to intervene," Geisbert said. "If someone has full-blown Ebola hemorrhagic virus, there is no drug on the planet that is going to protect them. But in the monkey model, we do have drugs where, if you have an early stage of infection and an early stage of illness, some of them are pretty successful."
**********************
An earlier abstract:
Expert Rev Anti Infect Ther. 2006 Feb;4(1):67-76.
Development of treatment strategies to combat Ebola and Marburg viruses.
Paragas J, Geisbert TW.[Dr. Geisbert is referenced by USA Today, above]
Virology Division, US Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD 21702-5011, USA. jason.paragas@amedd.army.mil
Ebola and Marburg viruses are emerging/re-emerging pathogens that pose a significant threat to human health. These naturally occurring viral infections frequently cause a lethal hemorrhagic fever in humans and nonhuman primates. The disastrous consequences of infection with these viruses have been pursued as potential biological weapons. To date, there are no therapeutic options available for the prophylaxis or treatment of infected individuals. The recognition that Ebola and Marburg viruses may be exploited as biological weapons has resulted in major efforts to develop modalities to counter infection. In this review, select technologies and approaches will be highlighted as part of the critical path for the development of therapeutics to ameliorate the invariably devastating outcomes of human filoviral infections.
*********************
A 2010 PR from PPHM, referencing effectiveness of its monoclonal antibody, Bavituximab, in treating viral fevers[VHFs], including Ebola:
I understand government funding[DTRA] for above project was not renewed in 2011[confirmation of that appears in PPHM IBOX]. Current status is unknown to me. Viral indications are still on the table at PPHM.
Market Data 
Markets 
AI
